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OrthologContinuous exposure to high concentrations of hexavalent chromium [Cr(VI)] in drinking water results in in-
testinal tumors in mice but not rats. Concentration-dependent gene expression effects were evaluated in fe-
male F344 rat duodenal and jejunal epithelia following 7 and 90 days of exposure to 0.3–520 mg/L (as
sodium dichromate dihydrate, SDD) in drinking water. Whole-genome microarrays identiﬁed 3269 and
1815 duodenal, and 4557 and 1534 jejunal differentially expressed genes at 8 and 91 days, respectively,
with signiﬁcant overlaps between the intestinal segments. Functional annotation identiﬁed gene expression
changes associated with oxidative stress, cell cycle, cell death, and immune response that were consistent
with reported changes in redox status and histopathology. Comparative analysis with B6C3F1 mouse data
from a similarly designed study identiﬁed 2790 differentially expressed rat orthologs in the duodenum com-
pared to 5013 mouse orthologs at day 8, and only 1504 rat and 3484 mouse orthologs at day 91. Automated
dose–response modeling resulted in similar median EC50s in the rodent duodenal and jejunal mucosae. Com-
parative examination of differentially expressed genes also identiﬁed divergently regulated orthologs. Com-
parable numbers of differentially expressed genes were observed at equivalent Cr concentrations (μg Cr/g
duodenum). However, mice accumulated higher Cr levels than rats at ≥170 mg/L SDD, resulting in a ~2-
fold increase in the number of differentially expressed genes. These qualitative and quantitative differences
in differential gene expression, which correlate with differences in tissue dose, likely contribute to the dispa-
rate intestinal tumor outcomes.
© 2012 Elsevier Inc.Open access under CC BY-NC-ND license.Introduction
Hexavalent chromium [Cr(VI)] is a recognized lung carcinogen
(IARC, 1990). The structural similarity of chromate to phosphate
and sulfate facilitates its uptake with potential risks of cancer in
humans (Costa, 1997). In vitro studies suggest Cr(VI) compounds
are cytotoxic and genotoxic, and form Cr-DNA adducts (Biedermann
and Landolph, 1987, 1990; Patierno et al., 1988; Zhitkovich, 2005,
2011), while others suggest that Cr(VI)-induced carcinogenicity
may involve epigenetic mechanisms (Arita and Costa, 2009; Sun et
al., 2011). Although, environmental levels of CrV(VI) are thought to
pose a minimal risk due to reduction to less toxic Cr(III) by bodily
ﬂuids and cellular constituents (De Flora et al., 1997; Proctor et al.,
2002; U.S. EPA, 1991), chronic exposure to high concentrations of
Cr(VI), in the form of sodium dichromate dihydrate (SDD), resulted
in intestinal tumors in mice but not rats (NTP, 2008).ry & Molecular Biology, Center
Wilson Road, Michigan State
517 353 9334.
i).
-NC-ND license.To further investigate the key events involved in the mode of ac-
tion (MOA) of intestinal tumor development, a complementary series
of comparative drinking water studies was conducted in female F344
rats and B6C3F1 mice (Kopec et al., 2012; Thompson et al., 2011a,
2011b, 2012). Both species exhibit similar biochemical and histologi-
cal evidence of oxidative stress, villous cytotoxicity, and crypt hyper-
plasia. Our mouse intestinal epithelial gene expression study reported
SDD-elicited dose-dependent differential gene expression consistent
with the proposed MOA (Thompson et al., 2011b), as well as identiﬁed
other over-represented functions and affected pathways (Kopec et al.,
2012). Given the similarity of several responses in mice and rats follow-
ing exposure to SDD in drinking water, comparative studies were
designed to investigate species-speciﬁc effects that may explain the dif-
ferent tumor outcomes.
More speciﬁcally, the same study design and treatment regimen
(7 and 90 days) was used to obtain duodenal and jejunal epithelial
tissues from SDD-treated rats for whole-genomemicroarray proﬁling.
In addition to analysis for over-represented functions and phenotyp-
ically anchoring differential gene expression to gross physiology, his-
topathology, and biochemical effects from complementary studies
(Thompson et al., 2012), rat and mouse gene expression data were
systematically compared using the same analysis methods (Kopec et
125A.K. Kopec et al. / Toxicology and Applied Pharmacology 262 (2012) 124–138al., 2012). Qualitative and quantitative differences in the number and
types of differentially expressed genes were identiﬁed that not only
support a proposed MOA involving oxidative stress, cytotoxicity, cell
proliferation, and DNA modiﬁcation but also suggest that the rat is
less responsive to SDD. These differences in SDD-elicited differential
gene expression may contribute to the different tumor outcomes.
Materials and methods
Animal husbandry and study design. Detailed descriptions of the
test substance, animal husbandry, and study design have been de-
scribed (Thompson et al., 2011b, 2012). Brieﬂy, Southern Research In-
stitute (Birmingham, AL) acclimatized 4–5 week old female Fischer
rats (Charles Rivers Laboratories International, Stone Ridge, NY) for
a minimum of 7 days with free access to irradiated NTP-200 wafers
(Zeigler Bros, Gardners, PA). Animals were continuously exposed to
sodium dichromate dihydrate (SDD) dissolved in tap water at 0, 0.3,
4, 60, 170 and 520 mg/L, corresponding to 0, 0.1, 1.4, 20.9, 59.3, and
181 mg/L Cr(VI) for 7 and 90 days (referred to as day 8 and day 91).
Rodents were euthanized using CO2 and intestinal sections were col-
lected and ﬂushed with ice-cold phosphate buffered saline. Duodenal
and jejunal sections were cut longitudinally and the epithelium was
scraped using disposable sterile plastic spatulas (VWR International)
into vials containing ~1 mL of TRIzol (Invitrogen, Carlsbad, CA) and
snap-frozen in liquid nitrogen. The samples were stored at −80 °C
and shipped on dry ice to Michigan State University for gene expres-
sion analysis. All procedures were carried out with the approval of the
Institutional Animal Care and Use Committee at Southern Research
Institute.
RNA isolation. Frozen samples were homogenized using a Mixer
Mill 300 tissue homogenizer (Retsch, Germany). Total RNA was iso-
lated according to the manufacturer's protocol with an additional
acid phenol:chloroform extraction. Brieﬂy, chloroform was added to
samples (0.2 mL per 1 mL of TRIzol), shaken vigorously by hand for
15 s, incubated for 2–3 min at room temperature and centrifuged at
12,000×g for 15 min at 4 °C. All centrifugation steps were carried
out at 12,000×g at 4 °C. Upper aqueous phase was collected and equal
volumeof acid phenol:chloroform5:1 (Sigma-Aldrich)was added. Sam-
ples were shaken by inversion and centrifuged for 10 min. Upper phase
was collected and precipitated with ice-cold 100% isopropanol for at
least 1 h at −20 °C, after which samples were centrifuged for 15 min.
Supernatant was removed and RNA pellets washed with 70% ethanol,
vortexed and centrifuged for 10 min. Ethanol was discarded and pellets
were air dried prior to resuspension in RNA storage solution (Ambion
Inc., Austin, TX). Samples were incubated in a water bath at 55 °C for
10 min to aid resuspension and stored at−80 °C prior to further analy-
sis. RNAwas quantiﬁed (A260), and quality of each sample was assessed
by evaluation of the A260/A280 ratio and by visual inspection of 1 μg total
RNA on a denaturing gel.
Microarray analysis. Dose-dependent changes in gene expression
were examined using rat 4×44 K Agilent whole-genome oligonucle-
otide microarrays (version 1, Agilent Technologies, Inc., Santa Clara,
CA). Treated samples were co-hybridized with vehicle controls to in-
dividual arrays according to the manufacturer's protocol (Agilent
Manual: G4140-90050 v. 5.0.1). All hybridizations were performed
with three independent biological replicates for treated and control
tissues (i.e., RNA samples were not pooled) and independent labeling
of each sample (Cy3 and Cy5, including dye swap) for each treatment
group at each time point (for a total of 60 microarrays at 8 and
91 days). Microarrays were scanned at 532 nm (Cy3) and 635 nm
(Cy5) on a GenePix 4000B scanner (Molecular Devices, Union City,
CA). Images were analyzed for feature and background intensities
using GenePix Pro 6.0 software (Molecular Devices). All data passed
a quality assurance protocol (Burgoon et al., 2005) and deposited inTIMS dbZach data management system (Burgoon and Zacharewski,
2007). Microarray data were normalized using a semi-parametric ap-
proach (Eckel et al., 2005) and the posterior probability P1(t) values
were calculated using an empirical Bayes method based on a per gene
and dose basis usingmodel-based t values (Eckel et al., 2004). Gene ex-
pression data were ranked and prioritized using |fold change|>1.5 and
statistical P1(t) value>0.999 criteria to identify differentially expressed
genes.
Dose–response modeling. Dose–response modeling was performed
using the ToxResponse Modeler, which identiﬁes the best-ﬁt between
ﬁve different mathematical models (linear, exponential, Gaussian,
sigmoidal, and quadratic) (Burgoon and Zacharewski, 2008). The al-
gorithm then identiﬁes the best-ﬁt from the ﬁve best in-class models
for subsequent half maximal effective concentration (EC50) calcula-
tions. Microarray data sets were ﬁrst sorted using more stringent
criteria (|fold change|>2 and P1(t)>0.999 cut-off in the 520 mg/L
SDD group), and then examined for genes exhibiting a sigmoidal dose–
response. EC50 values were only determined for genes exhibiting a sig-
moidal dose–response curve.
Quantitative real-time PCR (QRT-PCR). Total RNA was reverse tran-
scribed to cDNA and PCR ampliﬁed on an Applied Biosystems PRISM
7500 Sequence Detection. Supplementary Table S1 provides the names,
gene symbols, accession numbers, primer sequences, and amplicon
sizes. cDNAs were quantiﬁed using a standard curve approach and the
copy number of each sample was standardized to 3 housekeeping
genes to control for differences in RNA loading, quality, and cDNA syn-
thesis (Vandesompele et al., 2002). For graphing purposes (GraphPad
Prism 5.0), the relative expression levels were scaled such that the
expression level of the time-matched control group was equal to
one.
Functional gene annotation and statistical analysis. Annotation and
functional categorizations of differentially regulated genes were per-
formedusingDatabase for Annotation, Visualization and IntegratedDis-
covery (DAVID) (Dennis et al., 2003) and Ingenuity Pathway Analysis
(IPA, Ingenuity Systems, Redwood City, CA). For cross-species compar-
isons, HomoloGeneID was used to identify differentially expressed
orthologous genes. Hierarchical clustering (average linkage method;
Pearson correlation) was performed using MultiExperiment Viewer
(MeV v. 4.6.0) implemented in the TM4 microarray software suite
(Saeed et al., 2003). QRT-PCR statistical analyses were performed with
SAS 9.2 (SAS Institute, Cary, NC). Unless stated otherwise, all data
were analyzed by analysis of variance (ANOVA) followed by Dunnett's
post hoc test. Differences between treatment groups were considered
signiﬁcant when pb0.05.
Results
Rat intestinal differential gene expression at day 8
Microarray analysis (|fold change|>1.5, P1(t)>0.999) identiﬁed
3269 duodenal and 4557 jejunal differentially expressed genes (at
one or more doses) out of 17,142 unique annotated genes repre-
sented on the 4×44K Agilent microarray at day 8. Duodenal and jeju-
nal differential gene expression increased with dose (Fig. 1A).
Comparative analysis identiﬁed 2312 genes differentially expressed
(|fold change|>1.5, P1(t)>0.999) in both intestinal sections (Fig. 1B).
Relaxing the ﬁltering criteria (|fold change|>1.2 and P1(t)>0.9) for
the union of differentially expressed duodenal (3269) and jejunal
(4557) genes, to avoid exclusion of genes bordering the more stringent
cut-offs, increased the number of overlapping genes to 4240 (Fig. 1C).
This suggests that SDD elicited the expression of similar genes in the
rat duodenal and jejunal epithelia. However, duodenal differential
gene expression exhibited greater efﬁcacy (−31.2- to 54.5-fold)
CB
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Fig. 1. Comparative analysis of differentially expressed genes in rat (Rn) duodenal (Duo) and jejunal (Jej) epithelial samples (A–C) at day 8 and (D–F) at day 91. (A, D) Number of
differentially expressed genes (|fold change|>1.5, P1(t)>0.999) in the duodenum and jejunum at 8 and 91 days. Differentially expressed duodenal and jejunal genes were com-
pared using (B, E) stringent (|fold change|>1.5, P1(t)>0.999) and (C, F) relaxed (|fold change|>1.2, P1(t)>0.9) ﬁltering criteria. Numbers in Venn diagrams represent unique
genes.
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S2A–B).Rat intestinal differential gene expression at day 91
At day 91, 1815 duodenal and 1534 jejunal genes were differen-
tially expressed (|fold change|>1.5, P1(t)>0.999) (Fig. 1D), repre-
senting decreases of 56% and 66%, respectively, in the number of
unique differentially expressed genes compared to day 8, potentially
due to adaptation to Cr(VI) exposure. Approximately 765 genes over-
lapped between the duodenal and jejunal epithelia, which increased
to 2151 genes when using relaxed criteria (|fold change|>1.2 and
P1(t)>0.9) indicating similar responses between the two tissues
(Figs. 1E–F). Relative fold induction at the highest dosewas comparable
for both tissues (up to 19.4-fold), but duodenal epithelium showed
greater suppression (−26.5-fold) of gene expression relative to jeju-
num (−12.4-fold) (Supplementary Tables S3A–B).Dose–response modeling of rat intestinal differential gene expression
Probes with a |fold change|>2 and P1(t)>0.999 at 520 mg/L SDD
were selected for ToxResponse analysis (Burgoon and Zacharewski,
2008). Of the 1572 differentially expressed probes (943 unique genes)
at day 8, 1269 (744 unique genes) exhibited a sigmoidal dose-response
with ~67% having EC50s between 0.3 and 10 mg/L SDD (Fig. 2A). In jeju-
nal samples, 1934 probes (1021 unique genes) exhibited a sigmoidal
dose–response with 65% having EC50s between 10 and 100 mg/L SDD
(Fig. 2B). DAVID analysis of the 858 duodenal genes with EC50s
b10mg/L SDD identiﬁed over-represented functions associated with
protein synthesis, translation and ribosome-related genes. Eukaryotic
translation elongation and initiation factors (Eef1b2, Eef1e1, Eif2b3,
Eif2s1, Eif2s2) and ribosomal proteins (Rpl13, Rps3, Rps5, Rps10,
Rps27) exhibited sustained induction (~2-fold) across 4–520 mg/L
SDD with EC50sb10 mg/L. At day 91, only 310 duodenal and 167
jejunal genes exhibited a sigmoidal dose–response with >72% hav-
ing EC50s between 10 and 100 mg/L SDD (Supplementary Fig. S1).
AB
Fig. 2. Automated dose–response modeling of (A) duodenal and (B) jejunal gene expression data at day 8. ToxResponse modeler identiﬁed the best ﬁt model and was used to cal-
culate EC50 values. A signiﬁcant number of differentially expressed genes exhibited a sigmoidal dose–response proﬁle, with more sensitive duodenum exhibiting ~67% of EC50
values between 0.3 and 10 mg/L SDD and 65% of jejunal EC50s between 10 and 100 mg/L SDD.
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compared to the median jejunal EC50 (5 vs. 52 mg/L), suggesting
that the greater differential gene expression potency and efﬁcacy of
SDD decreased as it passed from the duodenum to the jejunum. At
day 91, the median rat duodenum and jejunum EC50s were compara-
ble (49 vs. 52 mg/L SDD).
Phenotypic anchoring of rat differential gene expression responses
Over-represented functions associated with differential gene ex-
pression were phenotypically anchored to complementary histopa-
thology and biochemical data (Table 1). The reduction in the GSH/
GSSG ratio is suggestive of intestinal epithelium oxidative stress
(Thompson et al., 2012). Nrf2 (Nfe2l2) induction (~2.6-fold), and sub-
sequent expression of downstream targets (up to 2.7-fold) is consistent
with an oxidative stress response. For example, ubiquitination and pro-
teasomal degradation proteins (Vcp, Usp14 and Ube2k), chaperone and
stress proteins (Stip1, Cct7, Erp29), and antioxidant proteins (Atf4,
Gpx2, and Prdx1) are consistent with oxidative stress. Interestingly,
EC50s of 4.2 and 14.2 mg/L SDD for Nrf2 in the duodenum and jejunum
at day 8, respectively, provide further evidence that gene expression ca-
pability decreased as SDD passed from the duodenum to the jejunum.
ToxResponse modeler also calculated EC50 values less than 5.0 mg/L
SDD for Nrf2-regulated Usp14, Cct7, and Erp29 at day 8. The Nrf2-
mediated oxidative stress response was also observed at day 91 andselect QRT-PCR veriﬁed genes included the induction of Nrf2, Gclc and
Gpx2 (Fig. 3).
Moreover, SDD induced trefoil factor 1 (Tff1), a small secreted pro-
tein involved in cell growth that stabilizes the gastrointestinal mucosa
and provides a physical barrier against toxic agents. Hydrogen perox-
ide also induces Tff1 (Balcer-Kubiczek et al., 2002), while oxidative
stress induced by indomethacin and ROS production is reduced by
TFF1 (Chattopadhyay et al., 2006; Marchbank et al., 1998), further
suggesting oxidative stress protection. Tff1 was induced >10-fold in
rats (EC50 Duodenum and Jejunum Day 8=4.2 and 35.3 mg/L SDD), and
53-fold in mice. The induction of Tff1 is consistent with oxidative
stress in the rat jejunum (Thompson et al., 2012), and likely repre-
sents an adaptive response to SDD.
Immune response genes (e.g., Acp5, Anxa5, C3, Ccl24 Cxcl12, Kitlg,
Il1rl1, Il33 and C1qa) were also differentially expressed (Table 1), con-
sistent with the mild to marked histiocytic inﬁltration at days 8 and
91 (Thompson et al., 2012). Interestingly, Il1rl1 (5- to 10.9-fold) and
Il33 (4.5- to 5.9-fold) exhibited the greatest fold changes with EC50s
of 6.8 and 5.4 mg/L SDD, respectively, in the duodenum at day 8.
The mouse orthologs were also highly induced immune response
genes, although their efﬁcacy of induction was lower with higher
EC50s (Kopec et al., 2012).
Several cell cycle, growth and proliferation genes exhibited dose-
dependent induction including Myc, Tp53 and their downstream tar-
gets. SDD also induced cyclin-dependent kinases and cell division
Table 1
Functional categorization and regulation of differentially expressed genes in response to 0.3–520 mg/L SDD after 8 and 91 days of exposure.
Functional category Entrez
GeneID
Gene name Gene
symbol
Duodenum
(day 8)
Jejunum
(day 8)
Duodenum
(day 91)
Jejunum
(day 91)
Fold
change
EC50
(mg/L)
Fold
change
EC50
(mg/L)
Fold
change
EC50
(mg/L)
Fold
change
EC50
(mg/L)
Oxidative stress 78959 Aldo-keto reductase family 1, member A1
(aldehyde reductase)
Akr1a1 1.6 ND 1.5 ND 1.2 ND 1.3a ND
24185 V-akt murine thymoma viral oncogene
homolog 1
Akt1 1.3 ND 1.6 42.9 1.4 ND 1.4a ND
79255 Activating transcription factor 4
(tax-responsive enhancer element B67)
Atf4 1.9 89.4 1.5 9.2 1.5 ND 1.4 ND
297406 Chaperonin containing Tcp1, subunit 7 (eta) Cct7 2.6 4.4 2.4 4.5 1.7 13.2 1.6 172.3
117030 Endoplasmic reticulum protein 29 Erp29 2.4 4.5 2.4 53.5 1.8 17.9 1.4a ND
314322 FBJ osteosarcoma oncogene Fos −2.0 ND −2.0 ND −1.8 ND NC ND
25283 Glutamate-cysteine ligase, catalytic subunit Gclc 1.6 ND 1.9 13.1 1.6 ND 1.5 4.6
29326 Glutathione peroxidase 2 Gpx2 2.7 69.6 2.4 3.6 2.3 16.3 2.1 ND
83619 Nuclear factor, erythroid derived 2, like 2 Nfe2l2 2.6 4.2 2.4 14.2 2.2 5.9 1.7 4.7
117254 Peroxiredoxin 1 Prdx1 2.2 4.6 2.0 3.9 1.5 ND 1.5 72.6
192277 Stress-induced phosphoprotein 1 Stip1 1.9 ND 1.6 60.1 1.5 ND NC ND
289623 Ubiquitin-conjugating enzyme E2K
(UBC1 homolog, yeast)
Ube2k 2.0 4.8 1.5 ND 1.5 4.4 NC ND
291796 Ubiquitin speciﬁc peptidase 14 Usp14 2.2 4.3 1.5 69.5 1.6 50.5 NC ND
116643 Valosin-containing protein Vcp 1.8 4.4 1.5 128.1 1.3 ND 1.3 ND
117270 Trefoil factor 1 Tff1 13.6 4.2 11.1 35.3 NC ND 10.6 25.6
Immune response 25732 Acid phosphatase 5, tartrate resistant Acp5 2.6 182.9 1.8 48.6 2.0 49.1 1.6 ND
25673 Annexin A5 Anxa5 2.9 6.5 3 5.2 2.1 4.8 1.8 ND
298566 Complement component 1,
q subcomponent, A chain
C1qa 3.0 4.6 2.5 4.3 2.3 82.7 1.7 114.8
24232 Complement component 3 C3 2.3 5.1 NC ND 2.1 17.9 1.5 10.7
288593 Chemokine (C-C motif) ligand 24 Ccl24 1.5a ND 1.5 ND 1.6 79.1 1.3a ND
25406 Cd44 molecule Cd44 3.7 3.9 2.2a ND 2.5 26.6 1.6a ND
24772 Chemokine (C-X-C motif) ligand 12
(stromal cell-derived factor 1)
Cxcl12 1.9 3.2 2.5a ND 2.0 4.4 1.8 ND
25441 Fc fragment of IgE, high afﬁnity I,
receptor for; gamma polypeptide
Fcer1g 1.5 ND NC ND 1.5 51.7 NC ND
29197 Interleukin 18 Il18 1.6 83.4 1.3 ND 1.5a ND 1.4a ND
24494 Interleukin 1 beta Il1b 1.3 ND 1.3 ND 1.6 ND 1.6 59.4
25556 Interleukin 1 receptor-like 1 Il1rl1 10.9 6.8 9.5 10.4 5.0 144.6 5.9 68.2
361749 Interleukin 33 Il33 5.9 5.4 5.6 67.7 4.5 31.8 3.9 47.3
60427 KIT ligand Kitlg 2.3 3.9 1.8 4.4 1.6 4.4 NC ND
297604 Lymphotoxin beta receptor
(TNFR superfamily, member 3)
Ltbr 1.4a ND 1.6 233.0 1.6 6.1 1.4 ND
Protein synthesis 64530 CCHC-type zinc ﬁnger, nucleic acid
binding protein
Cnbp 2.1 4.5 1.9 4.3 1.4 ND 1.5 161.9
288923 Deoxyhypusine synthase Dhps 1.8 4.2 1.9 53.8 1.6 28.5 1.4 ND
363241 Eukaryotic translation elongation
factor 1 beta 2
Eef1b2 2.1 4.0 1.7 3.6 1.6 4.3 NC ND
300033 Eukaryotic translation elongation factor 1
delta (guanine nucleotide exchange protein)
Eef1d 1.9 4.7 2.1 72.7 1.5a 4.4 NC ND
303746 Mitochondrial ribosomal protein L12 Mrpl12 1.6 4.2 1.6 50.9 1.4 ND NC ND
299938 Mitochondrial ribosomal protein L13 Mrpl13 1.8 4.1 1.7 77.9 1.4a ND NC ND
81765 Ribosomal protein L13 Rpl13 2.0 4.5 2.1 22.1 1.7 6.9 NC ND
245981 Ribosomal protein L15 Rpl15 2.6 56.5 2.4 56.6 1.9 7.4 1.4a ND
81766 Ribosomal protein L18 Rpl18 2.1 64.1 2.1 37.5 1.7 23.4 NC ND
290641 Ribosomal protein L18A Rpl18a 2.0 4.1 1.7 47.5 1.6a 50.1 NC ND
81773 Ribosomal protein S10 Rps10 2.3 4.0 2.4 48.0 1.8 45.0 NC ND
29287 Ribosomal protein S19 Rps19 2.3 54.3 2.1 3.9 1.8 7.4 NC ND
122799 Ribosomal protein s25 Rps25 2.3 143.9 2.1 3.3 1.7 50.4 NC ND
266975 Seryl-tRNA synthetase Sars 2.0 49.1 2.1 173.5 1.5 51.1 1.4a ND
Cell cycle/cell growth
and proliferation
114512 Apoptosis antagonizing transcription factor Aatf 2.3 4.1 2.0 2.8 1.8a 5.7 NC ND
25203 Cyclin B1 Ccnb1 3.2 56.6 3.1 4.0 1.9a 8.0 NC ND
64515 Cell division cycle 20 homolog (S. cerevisiae) Cdc20 2.7 54.9 3.2 5.2 1.7a 6.7 NC ND
366381 Cell division cycle 26 Cdc26 1.8 4.8 1.3a ND 1.3 ND NC ND
114562 Cell division cycle 37 homolog (S. cerevisiae) Cdc37 1.9 5.4 1.6 99.3 1.5 14.8 1.4 ND
171456 CDK105 protein Cdk105 2.4 67.0 2.0 4.7 1.6 61.5 1.4 ND
362817 Cyclin dependent kinase 2 Cdk2 2.0 4.1 1.7a 190.1 1.7a 74.4 NC ND
688405 CDK2-associated protein 2 Cdk2ap2 2.1 4.4 2.1 115.2 1.7 57.0 1.4 ND
94201 Cyclin-dependent kinase 4 Cdk4 2.3 4.1 2.0 3.7 1.7a 5.2 NC ND
24330 Early growth response 1 Egr1 1.7 38.9 1.7 ND 1.6 48.5 NC ND
24482 Insulin-like growth factor 1 Igf1 2.9 3.9 2.9 67.0 2.7 34.2 1.4a ND
24577 Myelocytomatosis oncogene Myc 1.6 ND 2.0 ND 1.5 4.3 1.8 ND
25737 Proliferating cell nuclear antigen Pcna 2.1 4.1 2.1 5.0 1.5 6.0 1.7 ND
24842 Tumor protein p53 Tp53 1.7 ND 1.3 ND 1.6 ND NC ND
DNA damage
and repair
79116 APEX nuclease (multifunctional
DNA repair enzyme) 1
Apex1 2.6 4.0 2.7 4.1 NC ND 2.0a,⁎ ND
297093 Chromobox homolog 3 (HP1
gamma homolog, Drosophila)
Cbx3 1.8 68.3 2.1 ND NC ND 1.5a,⁎ ND
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Table 1 (continued)
Functional category Entrez
GeneID
Gene name Gene
symbol
Duodenum
(day 8)
Jejunum
(day 8)
Duodenum
(day 91)
Jejunum
(day 91)
Fold
change
EC50
(mg/L)
Fold
change
EC50
(mg/L)
Fold
change
EC50
(mg/L)
Fold
change
EC50
(mg/L)
305000 Exonuclease 1 Exo1 2.1 4.0 2.4 6.4 1.5a ND 1.7a,⁎ ND
84490 Flap structure-speciﬁc endonuclease 1 Fen1 2.6 4.2 2.5 107.5 NC ND 2.2a,⁎ ND
360704 High-mobility group nucleosome binding
domain 1
Hmgn1 2.8 4.3 3.0 3.9 1.7a 5.5 1.9a⁎ ND
81709 MutS homolog 2 (E. coli) Msh2 2.9 3.7 3.0 5.0 2.2 5.0 1.4 ND
81528 8-Oxoguanine DNA glycosylase Ogg1 1.8 4.3 1.6 5.8 1.3a ND NC ND
NC — no change; genes did not meet an absolute fold change of at least 1.2 and P1(t)>0.90.
EC50 values were calculated using ToxResponse Modeler (Burgoon and Zacharewski, 2008).
ND — not detected, EC50 values were not available for genes that did not meet the |fold change|>1.5 and P1(t)>0.999 cut-off in the 520 mg/L SDD group, or if the modeling
returned a Gaussian best ﬁt model.
a Maximum absolute fold change, P1(t)>0.90.
⁎ Single low-dose (0.3 mg/L SDD) (P1(t)>0.90) suppression.
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and Cdk105 up to 3.2-fold with EC50s between 3.9 and 115mg/L SDD.
Moreover, insulin-like growth factor 1 (Igf1) and proliferating cell nu-
clear antigen (Pcna; EC50 Duodenum and Jejunum Day 8=4.1 and 5.0 mg/L
SDD) were induced in the rat intestine. Mouse intestinal epithelium
showed comparable Pcna induction (~2-fold). Protein synthesis func-
tions including eukaryotic translation elongation and initiation (e.g.
Eef1b2 and Eef1d), as well as ribosomal proteins (e.g. Rps10, Rps9, and
Rps25) and seryl-tRNA synthetase (Sars) were also over-represented,
likely in support of cell growth and proliferation (Table 1).
DNA damage and modiﬁcation genes (Apex1, Ogg1, Cbx3, Exo1,
Fen1, Msh2, and Hmgn1) were also induced 1.6- to 3-fold at day 8 in
the rat with EC50sb10 mg/L SDD. However, unlike the sustained in-
duction of DNA repair genes in the mouse (Kopec et al., 2012), their
efﬁcacy was lower in the rat duodenum (Table 1). Notably, changes
in 8-isoprostane or 8-OHdG were not observed in the rat duode-
num at day 91 (Thompson et al., 2012). DNA damage/repair genes
were generally non-responsive in the jejunum with modest suppres-
sion (P1(t)>0.90) at low doses, despite a reduced GSSG/GSH ratio in-
dicative of oxidative stress at day 91 (Thompson et al., 2012). Overall,
jejunal gene expression was lower at day 91 compared to theA B
Fig. 3. QRT-PCR veriﬁcation of oxidative stress response genes including (A) Nrf2 (Nfe2l2), (
was examined by QRT-PCR. All fold changes were calculated relative to the time-matched v
array data, respectively, with the x-axis representing the SDD concentrations. The genes are
error (SE) of at least 3 independent biological replicates. Asterisks (*) indicate a signiﬁcantduodenum, consistent with decreasing SDD gene expression capacity
in transit from the duodenum to the jejunum due to the reduction of
Cr(VI) to Cr(III).
Comparison of temporal changes in rat duodenum (3269 genes at
day 8 vs. 1815 genes at 91) identiﬁed 1419 overlapping genes (|fold
change|>1.5 and P1(t)>0.999) that doubled to 3141 genes using
relaxed criteria (|fold change|>1.2 and P1(t)>0.90; Fig. 4A) with
comparable expression proﬁles (Fig. 4B). Functional analysis revealed
enrichment of cell cycle, DNAmetabolism, DNA replication, andDNA re-
pair only at day 8 (Fig. 4C), suggesting adaptation of the rat duodenum
over time. In contrast, cell cycle, DNAmetabolism, DNA replication, and
DNA repair were over-represented at both day 8 and 91 in mice, sug-
gesting greater mouse sensitivity to SDD while rats adapt to exposure
over time.Comparisons of gene expression changes in rats and mice — orthologous
intestinal differential gene expression at day 8
Rat and mouse intestinal differential gene expression was system-
atically compared in order to identify conserved and divergentC
B) Gclc, and (C) Gpx2 in the rat at 91 days. The same RNA used for Agilent microarrays
ehicle controls. Bars (left y-axis) and lines (right y-axis) represent QRT-PCR and micro-
displayed by their ofﬁcial gene symbols. The data are represented as mean±standard
change (pb0.05) for QRT-PCR results.
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Fig. 4. Temporal comparison of differential gene expression in rat duodenum at 8 and 91 days. (A) Number of differentially expressed genes (|fold change|>1.5, P1(t)>0.999) in the du-
odenumat 8 and 91 days. Differentially expressed duodenal geneswere compared using stringent (|fold change|>1.5, P1(t)>0.999) and relaxed (|fold change|>1.2, P1(t)>0.9)ﬁltering
criteria. Numbers in Venn diagrams represent unique genes. (B) Hierarchical clustering (average linkage, Pearson correlation) of the overlapping differentially expressed 3141 duodenal
genes (frompart A/bottom)was performedusingMeV software. Red and green represent induced and repressed genes, respectively. D8— day 8, D91— day 91. (C) Functional enrichment
of day 8 andday 91unique gene expression changes (frompart A/bottom) usingDAVID. The overall enrichment score (ES) for the group is based on the EASE scores (modiﬁed Fisher Exact
p-values) of each term members. The higher the ES score, the more enriched the annotation cluster is.
130 A.K. Kopec et al. / Toxicology and Applied Pharmacology 262 (2012) 124–138responses. Orthologs were identiﬁed using HomoloGene (PubMed),
which assesses DNA sequence similarity to identify orthologous
genes (i.e. same gene in different species) (Wheeler et al., 2004,
2006). Approximately 13,899 unique orthologs were identiﬁed from
the 17,142 and 21,307 unique annotated rat and mouse genes, re-
spectively, that are represented on their respective microarrays (Sup-
plementary Fig. S2). Of the ~13,899 unique orthologs, 2790 and 5013
exhibited differential expression in the rat and mouse duodena, re-
spectively (Fig. 5A). Reduced stringency increased the overlap from
1986 to 3909 orthologs (Figs. 5B–C). Overall, more unique orthologs
(~6×) were expressed in the mouse duodenal epithelia (1649 ortho-
logs) compared to the rat (259 orthologs).
Cross-species comparison of the jejunal gene expression identiﬁed
similar numbers of unique differentially expressed orthologs (3782 rat
and 3334 mouse) (Fig. 5D). As observed in the duodenum, overlapping
orthologs increased from 1576 to 3864 genes with reduced stringency
(Figs. 5E–F). Unlike the duodenum, the number of species-speciﬁc
differentially expressed genes was comparable (971 rat vs. 705
mouse). Hierarchical clustering of the duodenal (Fig. 6A) and jejunal
(Fig. 6B) overlapping orthologs revealed that at≤14 mg/L SDD cluster-
ing was more random. In contrast, differential gene expression at
60–520 mg/L SDD clustered according to species. Overall, the dose-
dependent induction/repression was consistent between mice and
rats. However, divergently regulated clusters were also identiﬁed
(Supplementary Fig. S3A).Orthologous intestinal differential gene expression at day 91
Cross-species analysis of day 91 duodenal responses identiﬁed
1504 and 3484 differentially expressed unique orthologs for the rat
and mouse, respectively (Fig. 7A). Comparative analysis identiﬁedthat 811 (|fold change|>1.5, P1(t)>0.999) and 2536 (|fold change|
>1.2, P1(t)>0.9) orthologs overlapped between the species. The
mouse duodenal epithelia expressed more (~5×) non-overlapping
unique orthologs compared to rat following 90 days of SDD exposure
(Figs. 7B–C). Similar comparisons of jejunal differential gene expres-
sion identiﬁed 1305 rat and 3620 mouse orthologs of which 729
were expressed in both species (Fig. 7D). Using relaxed criteria, the
overlap was comparable to the duodenal orthologs at day 91 (2772 je-
junal orthologs in Figs. 7E–F). Hierarchical clustering of overlapping du-
odenal and jejunal orthologs again showed species-speciﬁc clustering at
higher doses (Figs. 8A–B, Supplementary Fig. S3B).
Divergent orthologous gene expression at day 91
Correlation analysis indicates that 81% of the overlapping differen-
tially expressed duodenal orthologs exhibit similar patterns at day 91
(Fig. 9A, Supplementary Fig. S4). However, several divergently (in-
duced in one species, repressed in other) expressed orthologs
associated with the immune response (Ccl24, C3), ion transport
(Slc25a25), and growth factor/cytokine signaling (Areg) (Table 2)
were identiﬁed and veriﬁed by QRT-PCR (Fig. 9B, Supplementary
Fig. S5).
Species-speciﬁc orthologous gene expression in duodenum at day 91
Approximately, 61% (2536 out of 4177) of all orthologs were dif-
ferentially expressed in the rat and mouse duodena. However, 1392
orthologs exhibited mouse-speciﬁc differential expression com-
pared to only 249 in the rat (Fig. 7C). This qualitative (i.e. different
genes/orthologs) and quantitative (number of species-speciﬁc dif-
ferentially expressed orthologs) difference may contribute to the
FE
D
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Fig. 5. Comparative analysis of the differentially expressed orthologs in the rat (Rn) and mouse (Mm) (A–C) duodenal (Duo) and (D–F) jejunal (Jej) epithelial samples at day 8.
(A, D) Number of Rn and Mm differentially expressed orthologs (|fold change|>1.5, P1(t)>0.999) in the Duo and Jej at day 8. Differentially expressed duodenal and jejunal ortho-
logs were compared using (B, E) stringent (|fold change|>1.5, P1(t)>0.999) and (C, F) relaxed (|fold change|>1.2, P1(t)>0.9) ﬁltering criteria. Numbers in Venn diagrams rep-
resent unique orthologs. Note: 14 mg/L SDD was not tested in rats.
131A.K. Kopec et al. / Toxicology and Applied Pharmacology 262 (2012) 124–138species-speciﬁc tumor outcomes. Hierarchical clustering of species-
speciﬁc expression revealed most genes exhibited weaker potency
and efﬁcacy in the rat compared to the mouse (Supplementary Fig.
Fig. S6). Functional annotation of the 1392 mouse orthologs identi-
ﬁed enrichment of alanine and aspartate metabolism, FAK signaling,
and BRCA1-related DNA damage response. Genes associatedwith the
FAK signaling pathway (involved in cell cycle, proliferation and
migration) were mostly down-regulated or unaltered at various
concentrations (including Fak/Ptk2; data not shown). Functional
enrichment analysis of rat speciﬁc expression was compromised by
the small number of differentially expressed orthologs (249) but dididentify intrinsic prothrombin activation (mostly down-regulated) as
enriched.Dose–response comparisons of differential gene expression in rats and
mice — EC50 distribution for over-represented pathways
Overall, SDD elicited more dose-dependent differential expression
in mice (±2-fold at 520 mg/L SDD and P1(t)>0.999) than rats
(Table 3). Although median EC50s were comparable, comparing EC50
distributions of overlapping orthologous genes identiﬁed species-
A B
Fold change
-3 1 3
Species and SDD
concentration (mg/L)
Species and SDD
concentration (mg/L)
Duodenum Day 8 Jejunum Day 8
Fig. 6. Hierarchical clustering of the overlapping differentially expressed (A) duode-
nal and (B) jejunal orthologs at 8 days. Duodenal (1986) and jejunal (1576) orthologs
differentially expressed in the mouse and rat (from Figs. 5B and E) were used for hi-
erarchical clustering (average linkage, Pearson correlation) using MeV software. Red
and green represent induced and repressed orthologs, respectively.
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mentary Fig. S7). For example, rat duodenal orthologs had a lower
median (~10-fold) and EC50 range for Translation/Protein Biosynthesis,
Cell Cycle and Oxidoreductase, while Inﬂammatory Response showed
comparable median EC50s between the species at day 8 (Supplemen-
tary Fig. S7A). Differences in median EC50s were also identiﬁed for
over-represented functions associated with Ribosome (mouse 23.0
vs. rat 52.6 mg/L), Translation (mouse 26.8 vs. rat 46.0 mg/L), Cell
cycle (mouse 36.8 vs. rat 4.5 mg/L SDD) and Nucleoside binding
(mouse 52.5 vs. rat 6.1 mg/L SDD). However, other over-
represented functions such as Oxidoreductase, Immune response, Car-
bohydrate binding, Apoptosis, and Proteolysis exhibited comparable
median EC50s between the species at day 91 (Supplementary Fig.
S7B). EC50 distributions also exhibited different ranges (12–361 mg/
L for Oxidoreductase in mouse duodenum at day 8 compared to
33–54 mg/L range for Proteolysis in rat duodenum at 91 days). There-
fore, assessing the effect of SDD on a pathway based on a median EC50
is limited by a lack of information regarding the critical regulatory re-
actions that dictate sensitivity since regulation can also be post-
translational, and may not be directly reﬂected by differential gene
expression.1 Total Cr levels were also obtained for full jejunum lengths (~18 and 67 cm long in
mice and rats), whereas jejunal epithelial scrapings were collected from the proximal
6 cm, thus only duodenal tissue total Cr concentrations were used to anchor duodenal
differential gene expression.Comparative dose–response modeling using duodenal tissue
concentrations
Total chromium concentrations, including the most abundant tri-
valent and hexavalent chromium species, were measured in rodentsmall intestine at 91 days (Thompson et al., 2011b, 2012). Full length
duodenum was measured for total Cr tissue determination, whereas
full length duodenal epithelial scrapings (mucosa only) were used
for gene expression analyses in this and the previous study (Kopec
et al., 2012).1 At similar duodenal tissue concentrations, a comparable
number of genes were differentially expressed in both species. How-
ever, at ≥170 mg/L SDD mouse Cr levels were almost double rat
levels (42–61 μg/g compared to 26–32 μg/g), consistent with the
~2-fold increase in the number of differentially expressed genes
(Fig. 10A). Comparisons of the differentially expressed orthologs
at overlapping tissue Cr concentrations (b40 μg Cr/g duodenum:
0.3–520 mg/L SDD in the rat and 0.3–60 mg/L SDD in the mouse)
indicated considerable overlap (Fig. 10B).Discussion
Cr(VI)-elicited differential gene expression has been evaluated in
vitro and in vivo (D'Agostini et al., 2002; Dos Santos Ferreira et al.,
2007; Gavin et al., 2007; Hook et al., 2008; Izzotti et al., 2002;
Joseph et al., 2008; Pritchard et al., 2005; Sun et al., 2011; Ye and
Shi, 2001). However, this is the ﬁrst study to systematically compare
Cr(VI) responses in a target tissue of carcinogenic interest following
repeated exposure in drinking water. Overall, there was considerable
similarity in the responses between the two species. However, the
mouse intestinal tract was more responsive, and species-speciﬁc
responses were observed even after accounting for total chromium
tissue levels.
Orthologous rat and mouse responses were examined in order to
qualitatively examine differential expression. An ortholog represents
the equivalent gene in a different species that arose from the same
ancestral gene prior to divergence (speciation) (Mindell and Meyer,
2001). Comparative datasets were obtained using similar study de-
signs, exposure regimens, microarray platforms, statistical analysis
approaches and data interpretation methods to minimize confound-
ing variables and facilitate a more harmonized comparison. Over-
represented functional analysis was integrated with conserved and
species-speciﬁc differential expression and complementary histo-
pathological and biochemical data to further investigate the proposed
MOA involving saturation of reductive capacity, oxidative stress, in-
ﬂammation, cell proliferation and DNA damage (Thompson et al.,
2011a, 2011b, 2012).
High SDD doses in the mouse have been proposed to saturate
reductive capacity in the proximal GI tract resulting in Cr(VI)
passage into the small intestine leading to facilitated uptake and
duodenal neoplasms (NTP, 2008; Stout et al., 2009). Tissue data
also indicate that mice have higher chromium levels compared to
rats, suggesting differences in reductive capacity and/or Cr(VI) ab-
sorption (NTP, 2007, 2008; Thompson et al., 2011b, 2012), while
others argue there is negligible evidence that reductive capacity
was exceeded (NTP, 2008; Stern, 2010). However, the greater
number of differentially expressed orthologs in mice indicates
greater SDD-elicited gene expression activity, consistent with
lower reductive capacity in mice as compared to rats. Kinetics
study in rodent gastric contents also indicates that Cr(VI) reduc-
tion capacity is exceeded at ≥60 mg/L SDD in mice (Proctor
et al., in press). The lower loading of Cr(VI) per liter of gastric con-
tents and lower loading of Cr(VI) to the intestinal lumen in rats
compared to mice is in agreement with higher (~2-fold) total
chromium concentrations in the mouse duodenum at 170 and
CB
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Fig. 7. Comparative analysis of the differentially expressed orthologs in the rat (Rn) and mouse (Mm) (A–C) duodenal (Duo) and (D–F) jejunal (Jej) epithelial samples at day 91.
(A, D) Number of Rn and Mm differentially expressed orthologs (|fold change|>1.5, P1(t)>0.999) in the Duo and Jej at day 91. Differentially expressed duodenal and jejunal
orthologs were compared using (B, E) stringent (|fold change|>1.5, P1(t)>0.999) and (C, F) relaxed (|fold change|>1.2, P1(t)>0.9) ﬁltering criteria. Numbers in Venn diagrams
represent unique orthologs. Note: 14 mg/L SDD was not tested in rats.
133A.K. Kopec et al. / Toxicology and Applied Pharmacology 262 (2012) 124–138520 mg/L SDD (Proctor et al., in press; Thompson et al., 2011b,
2012). Further studies evaluating species-speciﬁc differences in
gastric ﬂuid composition, pH, gastric acid production and Cr(VI)
transport into the intestinal epithelium are required to further
elucidate pharmacokinetic differences relevant to human risk as-
sessment (Stern, 2010; Thompson et al., 2011a).
Intestinal epithelium health is inﬂuenced by redox balance
(Circu and Aw, 2011). Inhibition of de novo GSH synthesis has
been associated with loss of epithelial cell height, desquamation
of microvilli, mitochondrial swelling, and jejunal villous tip vacuoli-
zation that is mitigated by GSH supplementation (Martensson et al.,1990). These effects are similar to those elicited by concentrations
of Cr(VI) that led to redox changes (Thompson et al., 2011b,
2012). However, reductions in rat GSH/GSSG ratios (indicative of
oxidative stress) exhibit regional speciﬁcity with jejunal changes
only occurring at ≥60 mg/L at 91 days (and 520 mg/L SDD at
8 days). This suggests that rats possess greater reductive capacity
that provides additional oxidative stress protection as Cr(VI) escapes re-
duction and passes through the alimentary tract in agreement with the
proximal small intestine of rats excreting additional reductants (e.g.
cysteine) into the lumen (Dahm and Jones, 2000; Hagen et al., 1990).
In contrast, mouse GSH/GSSG reductions are observed at ≥14 mg/L,
2 As discussed in Thompson et al. (2012), rats in our study had higher mg/kg doses
compared to the NTP studies (2007, 2008), which likely explains why intestinal dam-
age and proliferation were not observed in those studies.
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Fig. 8. Hierarchical clustering of the overlapping differentially expressed (A) duodenal
and (B) jejunal orthologs at 91 days. Duodenal (811) and jejunal (729) orthologs dif-
ferentially expressed in the mouse and rat (from Figs. 7B and E) were used for hierar-
chical clustering (average linkage, Pearson correlation) using MeV software. Red and
green represent induced and repressed orthologs, respectively.
134 A.K. Kopec et al. / Toxicology and Applied Pharmacology 262 (2012) 124–138suggesting saturation of mouse reductive capacity, allowing Cr(VI) to
elicit oxidative stress in the small intestine that likely contributes to
tumor formation.
Activation of the Nrf2 pathway and the integrated stress/unfolded
protein response, and Tff1/pS2 induction are consistent with oxidative
stress (Kopec et al., 2012). Transcription Factor (TF) Analysis in IPA,
also predicted NRF2 and related TF activation involving heat shock
transcription (HSF1) and endoplasmic stress response (XBP1) expres-
sion (Table 4). Although NRF2, HSF1 and XBP1 were activated in both
species, ATF4 was only activated in the mouse (Table 4), suggesting
greater oxidative stress, consistent with the lower GSH/GSSG ratio
and increased cytoplasmic vacuolization in mice (Thompson et al.,
2011b, 2012).
SDD induction of Acp5, Anxa5, C1qa, C3, Cxcl12, and Il1rl1 is con-
sistent with histiocytic inﬁltration in the rat small intestine (NTP,
2007, 2008; Thompson et al., 2012) and increased duodenal cyto-
kine levels (Thompson et al., 2012). The inhibition of interferon
regulatory factors (IRF1/3/4/7) (Table 4), is also consistent with
suppression of mouse immune-related genes (Kopec et al., 2012).
Furthermore, SDD elicited dose-dependent induction of cell cycle,
growth and proliferation genes, such as Pcna and Myc, as well as
the activation of MYC and MYCN in both species (Table 4). Howev-
er, crypt hyperplasia was minimal in the rat compared to the
mouse (Thompson et al., 2011b, 2012), in agreement with mouse
E2F1, E2F2, E2F3, and FOXM1 activation at ≥170 mg/L (Table 4).
Only sustained proliferation in the presence of an inﬂammation-
rich microenvironment is reported to potentiate and/or promotetumor progression (Coussens and Werb, 2002). Therefore, the
lack of hyperplasia and the moderate/marked histiocytic inﬁltra-
tion in the 2-year NTP (2008) bioassay may not be sufﬁcient to
promote intestinal cancer in the rat following prolonged SDD ex-
posure.2 TF analysis also suggests that TP53 and RB1 tumor sup-
pressor activities are inhibited in the mouse (Table 4). Coupled
with MYC activation in both species, the mouse is potentially
more at risk for tumor development due to increased oncogene
activity and decreased tumor suppressor gene activity.
Induction of oxidative stress response genes and changes in GSH
and GSSG levels suggest possible oxidative DNA damage. However,
there is no increase in intestinal 8-OHdG DNA damage (De Flora et
al., 2008; Thompson et al., 2011b, 2012), possibly due to adaptation
following long term exposure. Nevertheless, SDD altered the ex-
pression of DNA damage and modiﬁcation genes, including Myc-
regulated Apex1, which repairs damaged DNA (Gelin et al., 2010;
Watson et al., 2002). In the rat, DNA damage differential gene
expression was the greatest at day 8 with negligible changes (at
low doses) at day 91. In contrast, the mouse exhibited sustained
(albeit lower relative to day 8) induction of DNA damage and repair
genes at 91 days (Kopec et al., 2012), consistent with intestinal
tumor development at later time points. This is consistent with
gene expression being a more sensitive biomarker for oxidative
DNA damage compared to other endpoints like 8-OHdG levels (Rusyn
et al., 2004).
Comparative analysis identiﬁed several divergently expressed
orthologs (Ccl24, C3, Areg, Wfdc1, and Slc25a25). Ccl24, involved in
eosinophil recruitment, is induced by IL-4 (Lezcano-Meza et al.,
2003; Schaefer et al., 2006), consistent with Ccl24 mRNA repression
and down-regulation of IL-4 levels in the rat duodenum (Thompson
et al., 2011b, 2012). Moreover, the rat showed enrichment of comple-
ment activation functions with C3 induction, which was repressed in
the mouse. C3 is induced by IL-1α in human kidney proximal tubular
epithelial cells (Gerritsma et al., 1996) and by TNFα in human gastric
cancer-derived cells (Kitano and Kitamura, 1993). C3 induction in the
rat is consistent with IL-1α induction in the duodenum (Thompson et
al., 2012), while C3 repression is in agreement with decreased TNFα
cytokine and mRNA levels in the mouse duodenum (Kopec et al.,
2012; Thompson et al., 2011b). Although clinical studies show activa-
tion of the complement immune system in cancer patients, tumor
cells may develop alternative mechanisms to inhibit complement ac-
tivation (Pio, 2006). Moreover, complement inhibitors facilitate
tumor growth (Caragine et al., 2002), consistent with C3 repression
in mouse and intestinal tumor development with continuous SDD ex-
posure. Areg, a ligand for the epidermal growth factor receptor
(EGFR), is expressed in human cancers, including colorectal and gas-
tric tumors (Katoh and Katoh, 2006). It is implicated in colon cancer
(Baker et al., 2011; Yarom and Jonker, 2011), and promotes intestinal
epithelial regeneration after radiation injury (Shao and Sheng, 2010).
Effective anti-EGFR colorectal cancer drugs, such as Cetuximab (Baker
et al., 2011), suggest that continued EGFR activation may increase
tumor development risk. Areg induction in the mouse and repression
in the rat are consistent with greater hyperplasia in the mouse
(Thompson et al., 2011b, 2012).Wfdc1, which regulates cell adhesion,
migration, proliferation and immunity, is suppressed in cancer cells,
and was repressed in the mouse but induced in the rat (Madar et
al., 2009; Ressler and Rowley, 2011). The calcium-dependent ATP-
Mg/Pi solute carrier Slc25a25, induced in mice and repressed in rats,
is involved in adenine nucleotide (AMP, ADP, ATP) mitochondrial
transport via phosphate exchange (Hagen et al., 2003). Cr(VI) could
A B
Fig. 9. (A) The correlation plot of 811 overlapping orthologs in the rat and mouse duodena at 91 days. The x-axis represents the correlation of microarray orthologous gene expres-
sion, while the y-axis represents the correlation between signiﬁcance values. Over 81% of orthologs (circles) are located within the upper right quadrant and exhibit good corre-
lation across gene expression proﬁles and signiﬁcance values with a few orthologs (e.g. Ccl24, C3, Areg, and Slc25a25) showing divergent differential expression between the
species. (B) QRT-PCR veriﬁcation of species-speciﬁc regulation of Ccl24, C3, Areg, and Slc25a25 expression in the rat and mouse duodena at day 91. The same RNA used for Agilent
microarrays was examined by QRT-PCR. All fold changes were calculated relative to the time-matched vehicle controls. Left and right y-axis represent QRT-PCR data for mouse and
rat, respectively, with the x-axis representing the SDD concentrations. The genes are displayed by their ofﬁcial gene symbols. The data are represented as mean±SE of at least 3
independent biological replicates. Color-coded asterisks (*) indicate a signiﬁcant change (pb0.05) within species.
135A.K. Kopec et al. / Toxicology and Applied Pharmacology 262 (2012) 124–138interfere with the mitochondrial function of Slc25a25 due to its simi-
larity with phosphate and sulfate ions (Salnikow and Zhitkovich,
2008).Table 2
Differentially expressed orthologs in duodenum at day 91.
Gene symbol Gene name
Up in mouse; down in rat
Acsl3 Acyl-CoA synthetase long-chain family member 3
Areg Amphiregulin
Ccl24 Chemokine (C-C motif) ligand 24
Gch1a GTP cyclohydrolase 1
Rgn Regucalcin (senescence marker protein-30)
RipK3 Receptor-interacting serine-threonine kinase 3
Up in rat; down in mouse
C3b Complement component 3
Cd1d1 CD1d1 molecule
Desb Desmin
Igfbp4a Insulin-like growth factor binding protein 4
Itpr1 Inositol 1,4,5-triphosphate receptor, type 1
Mcama Melanoma cell adhesion molecule
Ms4a6b Membrane-spanning 4-domains, subfamily A, member 6B
Pdia6a Protein disulﬁde isomerase family A, member 6
Pgcp Plasma glutamate carboxypeptidase
Samhd1 SAM domain and HD domain, 1
Sh3kbp1 SH3-domain kinase binding protein 1
Slc25a25b Solute carrier family 25, member 25
Smpdl3a Sphingomyelin phosphodiesterase, acid-like 3A
Tenc1 Tensin like C1 domain containing phosphatase (tensin 2)
Tfam Transcription factor A, mitochondrial
Wfdc1a WAP four-disulﬁde core domain 1
a Differentially expressed genes (±1.5‐fold) at ≥60 mg/L.
b Differentially expressed genes (±1.5‐fold) at 60 and 520 mg/L only.
All other genes were differentially expressed (±1.5-fold) at ≥170 mg/L.Rat differential expression exhibited dose-dependent induction,
albeit fewer genes were differentially expressed and with less efﬁcacy
compared to mice (Kopec et al., 2012). This difference in the number
of differentially expressed genes is consistent with SDD intake and
chromium levels. Comparison of the average daily dose of SDD (in
mg/kg) in the 520 mg/L groups indicates rats ingested 81 and
59 mg/kg SDD at 8 and 91 days, respectively, whereas mice ingested
87 and 89 mg/kg (Thompson et al., 2012). The lower ingested dose
in rats with prolonged exposure (due to weight gain), is consistent
with the more modest histological, biochemical, and transcriptional
changes compared to mice (Thompson et al., 2011b, 2012). There
were comparable numbers of differentially expressed genes in both
species at similar tissue concentrations. However, Cr levels at
520 mg/L SDD in the rat duodenum are lower than in the mouse at
170 and 520 mg/L SDD, the concentrations that elicited intestinal tu-
mors in the 2-year mouse study (NTP, 2008). Therefore, the proposed
MOA may only be relevant when tissue chromium loads achieve the
levels reported in mice and suggests that the intestinal carcinogenic-
ity of Cr(VI) is likely a high-dose phenomenon.
In summary, this study provides further evidence for the saturation
of reductive capacity, oxidative stress, inﬂammation, cell proliferationTable 3
Comparison of rat and mouse dose–response modeling.
Rat Mouse
Median
EC50
Sigmoidal
genes
Median
EC50
Sigmoidal
genes
Day 8 Duodenum 5 mg/L SDD 744 46 mg/L SDD 2559
Jejunum 52 mg/L SDD 1021 43 mg/L SDD 955
Day 91 Duodenum 49 mg/L SDD 310 39 mg/L SDD 1045
Jejunum 52 mg/L SDD 167 55 mg/L SDD 1049
Fold change > 1.5
P1(t) > 0.999
11911078 313
2582 orthologs
Fold change > 1.2
P1(t) > 0.9
617642 1323
Mm
(0.3-60 mg/L)
Rn
(0.3-520 mg/L)
2582 orthologs
Relax
criteria
Mm
(0.3-60 mg/L)
Rn
(0.3-520 mg/L)
A
B
Fig. 10. (A) Rat (Rn) and mouse (Mm) differential duodenal gene expression (|fold
change|>1.5, P1(t)>0.999) plotted as a function of average total duodenal Cr levels
(μg/g tissue) at 91 days. Comparison of differential ortholog expression vs. duodenal
tissue levels follows the same pattern with twice the number of orthologs expressed
in the mouse compared to rat. Note: the 520 mg/L SDD groups are shown in (A) for
clarity. (B) Number of Rn and Mm differentially expressed orthologs (|fold change|
>1.5, P1(t)>0.999) in the duodenum at day 91 using stringent (top) and relaxed (bot-
tom) ﬁltering criteria. Only mg/L SDD ranges resulting in similar μg Cr/g duodenum
(shown in (A)) are compared.
Table 4
Comparative transcription factor analysis (IPA) in duodenum at 91 days.
60 mg/L SDD 170 mg/L SDD 520 mg/L SDD
Mouse Rat Mouse Rat Mouse Rat
▲JUND ▲HMGA1 ▲ATF4 ▲HSF1 ▲ATF4 ▲CBL
▲MYC ▲KLF5 ▲E2F1 ▲ISL1 ▲E2F1 ▲HSF1
▲MYCN ▲MKL1 ▲E2F2 ▲JUND ▲E2F3 ▲HTT
▲NR1I2 ▲MYC ▲E2F3 ▲MYB ▲FLI1 ▲MYB
▲VD3-VDR-RXR ▲MYCN ▲FLI1 ▲MYC ▲FOXM1 ▲MYC
None▼ ▲NFE2L2 ▲FOXM1 ▲MYCN ▲HSF1 ▲MYCN
▲SATB1 ▲HSF1 ▲NFE2L2 ▲HSF2 ▲NFE2L2
AHR▼ ▲HSF2 ▲NR2F1 ▲LEF1 ▲POU4F1
CEBPA▼ ▲IKZF1 ▲POU4F1 ▲MDM2 ▲SATB1
CIITA▼ ▲LEF1 ▲SATB1 ▲MYC ▲SMAD1
HNF4A▼ ▲MDM2 ▲SKIL ▲MYCN ▲XBP1
IRF7▼ ▲MECP2 AHR▼ ▲NFE2L2 AHR▼
PPARA▼ ▲MYC CIITA▼ ▲NR2F1 CEBPB▼
PPARG▼ ▲MYCN CREBBP▼ ▲NRF1 CIITA▼
PPARGC1A▼ ▲NFE2L2 FOXO3▼ ▲PPARGC1B FOXO3▼
RXRA▼ ▲SATB1 HNF4A▼ ▲SATB1 HNF1A▼
▲SIRT2 KLF2▼ ▲SIRT2 HNF4A▼
▲SREBF1 MED1▼ ▲SREBF1 IRF3▼
▲SREBF2 MEOX2▼ ▲SREBF2 MED1▼
▲TBX2 PPARA▼ ▲TBX2 MYOD1▼
▲XBP1 PPARG▼ ▲THRa PPARA▼
▲ZBTB7B PPARGC1A▼ ▲ZBTB7B PPARD▼
CDKN2A▼ SPDEF▼ CDKN2A▼ PPARG▼
CIITA▼ STAT1▼ CIITA▼ PPARGC1A▼
FOXO3▼ FOXA2▼ PPARα-
RXRα▼
HNF1A▼ HNF4A▼ RUNX1▼
HNF4A▼ IRF1▼ STAT1▼
IRF1▼ IRF3▼
IRF3▼ IRF4▼
IRF4▼ IRF7▼
IRF7▼ KDM5B▼
KDM5B▼ MXI1▼
MXD1▼ Nfat
(family)▼
MXI1▼ PML▼
Nfat
(family) ▼
PPARA▼
NFATC2▼ PPARG▼
NR4A2▼ Rb▼
PPARA▼ RB1▼
Rb▼ SMARCB1▼
RELA▼ STAT1▼
SMARCB1▼ TAF4▼
STAT1▼ TCF3▼
STAT4▼ TOB1▼
TCF3▼ TP53▼
TOB1▼ ZEB1▼
TP53▼
ZEB1▼
Transcription regulators (TRs) in bold were altered in both species at one or more
doses.
Activated TRs are marked with ▲ (z-score>2.0), inhibited TRs are marked with ▼ (z-
scoreb−2) for differentially expressed mouse and rat genes meeting |fold change|
>1.5 and P1(t)>0.999.
a THR, thyroid hormone receptor.
136 A.K. Kopec et al. / Toxicology and Applied Pharmacology 262 (2012) 124–138and DNA damage. In addition, they are consistent with the more pro-
nounced apical responses, differences in Cr tissue levels, and the
greater number of differentially expressed genes observed in mice.
Species-speciﬁc gene expression and divergent regulation of ortho-
logs are also consistent with mouse-speciﬁc tumor development.
Pharmacokinetic differences, or other adaptive responses result in
lower tissue chromium levels and fewer differentially expressed
genes in rats. Additional studies are required to further elucidate dif-
ferences in differential gene expressions relevant to species-speciﬁc
outcomes.Supplementary data to this article can be found online at doi:10.
1016/j.taap.2012.04.026.Funding
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